ResultsIQ

ResultsIQ › Latest results › Fortis Healthcare Limited

Fortis Healthcare Limited Q1 FY27 earnings call summary

NSE: FORTIS · BSE: 532843

Earnings call of 7 Aug 2026, summarised by AI from the filing.

Fortis Q1 FY27 revenue ₹2,545 cr, up 17.5%; maintains 25% EBITDA margin guidance by FY28 after ESOP cost.

Key takeaways

  1. Revenue Consolidated revenue ₹2,545 cr, up 17.5% over Q1 FY26; hospital revenue ₹2,187 cr, up 19%.
  2. ESOP ESOP charge around ₹40 cr per quarter initially, falling to ₹30 cr then ₹25 cr.

Original filing on BSE

Fortis Healthcare Limited Q1 FY27 results

As filed: Revenue ₹2,545 cr (+17% year on year), EBITDA ₹537 cr (+9% year on year), PAT ₹273 cr (+2% year on year), EBITDA margin 21.1% (−155 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,365 cr (+18% year on year), EBITDA ₹532 cr (+22% year on year), PAT ₹271 cr (+44% year on year), EBITDA margin 22.5% (+79 bps). Score 65 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was in line with it. EBITDA margin rose 79 bps year on year. Revenue rose ₹358 cr on a year ago, more than the ₹221 cr it added the year before. Share price after the results: +0.3% in 28 days (Nifty 500: +2.2%).
  • Q3 FY26: Revenue ₹2,265 cr (+17% year on year), EBITDA ₹506 cr (+35% year on year), PAT ₹197 cr (+22% year on year), EBITDA margin 22.3% (+293 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 293 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Profit fell 23% from last quarter. Share price after the results: −8.4% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹2,331 cr (+17% year on year), EBITDA ₹556 cr (+28% year on year), PAT ₹329 cr (+70% year on year), EBITDA margin 23.9% (+197 bps). Score 66 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 197 bps year on year. Revenue rose ₹343 cr on a year ago, more than the ₹218 cr it added the year before. Share price after the results: −13.3% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹2,167 cr (+17% year on year), EBITDA ₹491 cr (+44% year on year), PAT ₹267 cr (+53% year on year), EBITDA margin 22.7% (+426 bps). Score 80 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin rose 426 bps year on year. Revenue rose ₹308 cr on a year ago, more than the ₹202 cr it added the year before. Share price after the results: +10.5% in 30 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹2,007 cr (+12% year on year), EBITDA ₹436 cr (+14% year on year), PAT ₹188 cr (+8% year on year), EBITDA margin 21.7% (+39 bps). Score 37 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin rose 39 bps year on year. Share price after the results: +14.8% in 28 days (Nifty 500: +6.9%).
  • Q3 FY25: Revenue ₹1,928 cr (+15% year on year), EBITDA ₹374 cr (+32% year on year), PAT ₹254 cr (+90% year on year), EBITDA margin 19.4% (+249 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin rose 249 bps year on year. Tax rate 9%. Revenue fell 3% from last quarter.
  • Q2 FY25: Revenue ₹1,988 cr (+12% year on year), EBITDA ₹435 cr (+32% year on year), PAT ₹193 cr (+40% year on year), EBITDA margin 21.9% (+329 bps). Score 68 of 100, Above trend. EBITDA margin rose 329 bps year on year. Consolidated profit +5% but standalone -58%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Fortis Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.